Insulin peglispro

Cat. No.:	HY-P4062
CAS No.:	1200440-65-8
Molecular Formula:	$C_{370}H_{566}N_{104}O_{110}S_4$
Molecular Weight:	8359.32
Sequence:	Chain1:Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Lys-Pro-Thrchain 2Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Asn(Disulfide chain 1 cys7-chain 2 cys7, Disulfide chain 1 cys19-chain 2 cys20, Disulfide chain 2 cys6-cys11)
Sequence Shortening:	Chain1:FVNQHLCGSHLVEALYLVCGERGFFYTKPTChain2:GIVEQCCTSICSLYQLENYCN(Disulfide chain 1 cys7-chain 2 cys7, Disulfide chain 1 cys19-chain 2 cys20, Disulfide chain 2 cys6-cys11)
Target:	Insulin Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins[1].
In Vivo	Insulin peglispro (BIL) (s.c., 17, 0.45 or 1.15 mg/kg/d, 52 week) has no effect on Crl:CD(SD) rat survival at any dose, resulting in some increase in body weight. Serum glucose concentrations are unaffected at an administered dose of 0.17 mg/kg, while 0.45 mg/kg shows lower serum glucose concentrations at 3 and 6 hours post-dose on day 1[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Richard A Byrd, et al. Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action. Toxicol Pathol. 2017 Apr;45(3):402-415.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA